Amphastar Pharmaceuticals Posts Modest Revenue Growth Amid Strategic Shift

Amphastar Pharmaceuticals, Inc. (NASDAQ: AMPH) reported Q3 2025 non‑GAAP earnings of $0.93 per diluted share, exceeding forecasts of roughly $0.83. Revenue came in at $191.8 million, almost flat year‑over‑year (vs. ~$191.2 million a year ago) but slightly ahead of analyst expectations (+3.96 %). The company highlighted a strategic pivot from generics toward higher‑margin proprietary and biosimilar products, citing growth in brands like BAQSIMI and Primatene MIST and a goal of achieving a 50 % proprietary‑product mix. That said, management expects the near term (2025) to remain flat for revenue, with return to growth projected for 2026 as the pipeline matures. #Amphastar #PharmaEarnings #GenericsToProprietary #HealthcareStrategy #SlimScan #GrowthStocks #CANSLIM